Romidepsin
Orphan Drug Cold Chain RequiredFDA Approved
Contents
Description
Romidepsin is a histone deacetylase (HDAC) inhibitor. It is approved for the treatment of cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL).
Indications & Therapeutic Use
Cutaneous T-cell lymphoma, Peripheral T-cell lymphoma, Mantle cell lymphoma
Linked Diseases:
mantle cell lymphoma
C85.7D020522
Global Availability (4 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Romidepsin — GNH India
8 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Browse all Romidepsin products on GNH IndiaProducts and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Romidepsin
| Generic Name | Romidepsin |
| Brands | 1 brand available |
| Active Ingredient | Romidepsin |
| Drug Class | Cutaneous T-cell lymphoma |
| Manufacturer | Celgene |
| Dosage Forms | IV infusion, 10mg/vial |
| Medical Code | L01XX41 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00078932 |
| Countries | 4 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations5 Validated Nodes